


Prevention for GBS perinatal disease: Which improvements for GBS screening?

Pierrette Melin

National Reference Centre for GBS Microbiology, University of Liege Medical Microbiology, University Hospital of Liege

SCREENING



INES

1

INTRODUCTION & BURDEN

Meridian 09.10.2012 INTRODUCTION & BURDEN GUIDELINES SCREENING VACCINE CONCLUSION

2

Streptococcus agalactiae or GBS



Gram positive cocci Catalase β-hemolytic CAMP test + Hippurate + Esculine-Orange pigment

10 capsular serotypes (Ia, Ib, II-IX)

1887, Noccard-Mollereau, bovine mastitis
1933, Group B Antigen
1964, severe neonatal sepsis
≻1970, N° 1 in neonatal infections



INTRODUCTION & BURDEN GUIDELINES

SCREENING

Group B streptococcal diseases in neonates

- Since the 1970s, leading cause of lifethreatening infections in newborns
 - Neonatal illness/death
 - Long-term disabilities
- Maternal morbidity
 - Along pregnancy
 - Peripartum

GLOBAL public health major concern !

Also in developing countries


- Serious diseases among elderly and adults with underlying diseases
 - Significant mortality


GBS Neonatal Infections

A. Schuchat, Clin Microb Rev 1998;11:497-513

GBS Neonatal Infections

A. Schuchat, Clin Microb Rev 1998;11:497-513






Burden of neonatal GBS early onset diseases in European countries


Location	Incidence per 1,000 live- births	Reference	
Spain	2 (1996) to 0.45 (2008)	Lopez Sastre et al. Acta Pediatr 2005	 Carriage rate Ethnicity ? Sub-reportin Systematic diagnostic approach? Virulence?
Belgium	2	<i>Melin, Indian J Med Res 2004</i>	
Eastern Europe	0.2 - 4	<i>Trijbels-Smeulders, Pediatr Infect Dis J 2004</i>	
Western Europe	0.3 - 2		
The Netherlands	1.9		- viruience?
Scandinavia	0.76 - 2		
Southern Europe	0.57 - 2		

Data assessing more accurately the true burden are needed

GBS EOD vertical transmission




GBS EOD vertical transmission



9

GBS EOD vertical transmission



GBS maternal colonization

Risk factor for early-onset disease (EOD) : vaginal GBS colonization <u>at delivery</u>

GBS carriers

- 10 35 % of women
- Clinical signs not predictive
- Dynamic condition
- Intestinal reservoir
- Prenatal cultures late in pregnancy <u>can predict</u> delivery status

Additional Risk Factors for Early-Onset GBS Disease

- u Obstetric factors:
 - u Prolonged rupture of membranes,
 - u Preterm delivery,
 - u Intrapartum fever
- u GBS bacteriuria
- u Previous infant with GBS disease
- u Immunologic:
 - u Low specific IgG to GBS capsular polysaccharide

No difference in occurrence either in GBS Positive or Negative women, except intrapartum fever

> Lorquet S., Melin P. & al. J Gynecol Obstet Biol Reprod 2005


GBS EOD - Belgian data

Incidence

- 1985 -1990: 3/1000 live births
- 1999, estimation : 2/1000 live births
- 2010, estimation : < 1/1000 live births</p>
- Meningitis : 10 %
- Mortality : 5 -10 %
- 60 % EOD (130 cases) : WITHOUT any maternal/obstetric risk factor except
 - colonization
- Prenatal screening
 - Recto-vaginal cultures : 13-35 % GBS Positive


P. Melin - 2001, 2007 - Reference laboratory for GBS.

Stages in the pathogenesis of GBS neonatal EOD : Bacterial & individual factors



- Universal prenatal screening-based strategy
- Risk-based strategy
- No guideline

GUIDELINES FOR PREVENTION OF GBS PERINATAL DISEASE




Which prevention strategy for GBS perinatal diseases

Intrapartum antibioprophylaxis
Immunoprophylaxis

Meridian 09.10.2012 INTRODUCTION & BURDEN GUIDELINES


SCREENING

Stages in the pathogenesis of GBS neonatal EOD : Bacterial & individual factors



Intrapartum antibioprophylaxis > 4 (2) hours before delivery

Stages in the pathogenesis of GBS neonatal EOD : Bacterial & individual factors



Prevention of perinatal GBS EOD

Intrapartum antibiotics

 Highly effective at preventing EOD in women at risk of transmitting GBS to their newborns (≥ 4 h)

(clinical trials in late 80s)

Risk-based strategy or Screening-based strategy



Meridian 09.10.2012

SCREENING

Prevention of perinatal GBS EOD


Screening-based strategy

INTRAPARTUM ANTIMICROBIAL PROPHYLAXIS

Main goal :

- To prevent 70 to 80 % of GBS EO cases Secondary :
- To reduce peripartum maternal morbidity

Impact of prevention practices Early- and Late-onset GBS Diseases in the 1990s, U.S.




Why is Screening more protective than the risk-based approach ?

Schrag S. et al. N Engl J Med 2002; 347:233-9

Broader coverage of « at-risk » population


- Captures colonized women without obstetric RF
- High level of compliance with recommendations
- Enhanced compliance with risk-based approach <u>cannot prevent as many</u> cases as universal screening

Impact of prevention practices Early- and Late-onset GBS Diseases, U.S.



Meridian 09.10.2012 INTRODUCTION & BURDEN GUIDELINES SCREENING

CONCLUSION




SCREENING

European strategies for prevention of GBS EOD

- Intrapartum antibioprophylaxis recommended
 - Screening-based strategy
 - Spain, 1998, 2003, revised 2012
 - France, 2001
 - Belgium, 2003, revision ongoing 2012
 - Germany, 1996, revised 2008
 - Switzerland, 2007
 - Risk-based strategy
 - UK, the Netherlands, Denmark
- No guidelines
 - Bulgaria, ...

25

Universal screening-based strategy for prevention of GBS perinatal disease






Meridian 09.10.2012 INTRODUCTION & BURDEN GUIDELINES SCREENING VACCINE CONCLUSION 27

Remaining burden of GBS EOD Missed opportunities

In spite of universal screening prevention strategy In spite the great progress Cases still occur

- Among remaining cases of EOD
 - Some may be preventable cases
 - Missed opportunities for (appropriate) IAP
 - False negative screening

Van Dyke MK, Phares CR, Lynfield R et al. N Engl J Med 2009 CDC revised guidelines 2010 Poyart C, Reglier-Poupet H, Tazi et al. Emerg Infect Dis 2008 DEVANI project, unpublished data 2011



SCREENING FOR GBS COLONIZATION

Antenatal GBS culture-based screening

Goal of GBS screening

To predict <u>GBS vaginal</u> (rectal) colonization at the time of <u>delivery</u>


Critical factors influencing accuracy

- Swabbed anatomic sites
- Timing of sampling
- Screening methods
 - Culture
 - Procedure
 - Media
 - Non-culture

From direct plating on blood agar Evolution of culture methods

Use of selective enrichment broth


- To maximize the isolation of GBS
- To avoid overgrowth of other organisms




Which agar or which combination?

+/- Blood agar









Workload - costs - extra-testing - non β-hemolytic GBS detection to be considered

Meridian 09.10.2012

INTRODUCTION & BURDEN

GUIDELINES


SCREENING

32

WHEN 35-37 weeks **WHO** ALL the pregnant women **Specimen** Vaginal + rectal swab(s) Collection **WITHOUT** speculum **Transport/collection device/condition Transport** (non nutritive medium: Amies/Stuart or Granada like tube) (type of swab)(Length and T°) **Request form** To specify prenatal « GBS » screening Laboratory procedure

(CDC 2010 - Belgian SCH 2003)

CONCLUSION



Transport-collection system & transport-storage condition

 Specimen storage in transport medium and detection of group B streptococci by culture.


Rosa-Fraile M. et al. J Clin Microbiol 2005, 43: 928-930

Recovery of group B streptococci (GBS) was assessed in 1,204 vaginorectal swabs stored in Amies transport medium at 4 or 21°C for 1 to 4 days either by direct inoculation onto Granada agar (GA) or by culture in blood These data indicate that viability of GBS is not fully preserved by storage of vaginorectal swabs in Amies transport medium, mainly if they are not stored under refrigeration.

Belgian Guidelines (2003, SHC)

"Specimens should be placed in a non-nutritive transport medium (e.g., Amies or Stuart's without charcoal). In these conditions, viability of GBS is warranted for at least 48 h at room temperature or in a fridge (2 - 8 $^{\circ}$ C).

Specimen labels should clearly identify that specimens are for group B streptococcal culture. Swabs should reach the lab within 48 h of collection."



Crucial conditions to optimize SCREENING

Transport-collection system & transport-storage condition Preliminary results (2012, NRC GBS)

- Use of a selective enrichment Lim broth (BD, Copan, bioMérieux)
 - At RT° up to 35° C
 - Rapid important amplification of GBS initial inoculum
 - Sustained viability > 4 days
 - Between 4-8° C
 - > 24 hours, continuous decrease of life GBS

- Use of a selective enrichment Granada medium (bioMérieux)
 - At RT° up to 35° C
 - Rapid important amplification of GBS initial inoculum
 - Sustained viability at RT°
 - Abrupt lost of viability at 35° C ≥ 48-72h
 - Between 4-8° C
 - > 24 hours, continuous decrease of life GBS


Prenatal culture-based screening: Limiting factors

Positive and negative predictive values

- False-negative results
 - Failure of GBS culture (oral ATB, feminine hygiene) or new acquisition
 - Up to 1/3 of GBS positive women at time of delivery
 - Continuing occurrence of EO GBS cases
- False-positive
 - Positive prenatal screening /negative at time of delivery
 - Unnecessary IAP

Need for more accurate predictor of intrapartum GBS vaginal colonization

Prenatal culture-based screening: Limiting factors




Prenatal culture-based screening combined with *illumigene®* Group B Streptococcus assay



A loop mediated isothermal amplification (LAMP) assay by Meridian Bioscience, Inc

- Broth enrichment followed by illumigene® GBS
 - Speed and accuracy





		GBS culture		
		Positive	Negative	
illumigene GBS	Positive	45	2	47
	Negative	5	188	193
		50	190	240

GBS Positive cultures: 20.7%

illumigene GBS vs GBS reference culture (all discrepancies were retested)

Sensitivity	90.0 %
Specificity	98.9 %
PPV	95.7 %
NPV	97.4 %
Efficiency	97.1 %

Meridian 09.10.2012

CONCLUSION

		GBS culture		
		Positive	Negative	
illumigene GBS	Positive	45	2 : PCR pos	47
	Negative	5	188	193
		50	190	240

GBS Positive cultures: 20.7%

illumigene GBS vs GBS reference culture /GBS DNA

Sensitivity	90.0 %	
Specificity	98.9 %	→ 100%
PPV	95.7 %	→ 100 %
NPV	97.4 %	
Efficiency	97.1 %	

		GBS culture		
		Positive	Negative	
illumigene GBS	Positive	45	2 : PCR pos	47
	Negative	2 positive 3 very rare GBS	188	193
		50	190	240

GBS Positive cultures: 20.7%

illumigene GBS vs GBS reference culture /GBS DNA

Sensitivity	90.0 %	→ 95.7%
Specificity	98.9 %	→ 100%
PPV	95.7 %	→ 100 %
NPV	97.4 %	→ 99 %
Efficiency	97.1 %	

Meridian 09.10.2012 INTRODUCTION & BURDEN GUIDELINES SCREENING VACCINE CONCLUSION 44

Easy to perform

- But training very important
 - Molecular amplification method
 - Need for different skill
 - Workflow
- Invalid results
 - CHU Liege
 - I negative retested "invalid"
 - AZ Sint Lucas, Gent, decreased rate with experience
 - 5 resolved as negative
 - 3 resolved as positive
- Short hands-on-time
- Short turn-around-time

- Speed and accuracy
- Good comparison to reference culture method
 - 100% specificity and positive predictive value
 - High sensitivity and negative predictive value
 - Identification of an 0.8% additional GBS positive specimen
 - Overall cost and logistic to be considered

Prenatal culture-based screening: Limiting factors


- Unknown GBS status at presentation for delivery
 - Screening performed but result not available
 - Women with no prenatal care

Risk based strategy

- 60% at GBS risk not identified
- > 10% of unnecessary IAP

Need for rapid accurate predictor of intrapartum GBS vaginal colonization

Alternative to GBS prenatal screening: intrapartum screening Theranostic approach



48

Intrapartum screening theranostic approach: expected advantages

- Inclusion of women without prenatal screening/care
- Identification of women with change of GBS status after 35-37 wks gestation
- Increased accuracy of vaginal GBS colonization status at time of labor & delivery




Real Time PCR for intrapartum screening

- Advance in PCR techniques & development of platforms
 - BD GeneOhm[™] Strep B Assay (+/- 1 hr) (in laboratory)
 - Xpert GBS, Cepheid (35-45 min) (can be performed as a POCT)



Real-time PCR, very promising, BUT ...

- Rapid, robust & accurate technology
- Still an expensive technology (specific equipment)
 - Cost effective ?
 - Need for more cost-effective clinical study
- Logistic
 - 24 hours 7 days
 - In the lab?
 - In the obstetrical department as a POCT ?
- In combination with prenatal screening strategy ?
 - CDC 2010 : for women with premature delivery or no prenatal care
- No antimicrobial result
 - In the future detection of R genes, but mixed microbiota !



CONCLUSION Take home messages

In Europe, as globally

Neonatal GBS diseases

- EOD and LOD, a public health concern
- IAP efficient for prevention of EOD
 - Best strategy still a matter of debate
 - Not 100% efficient
 - No effect on LOD
- IAP not widely recommended
- Need better data assessing more accurately the true burden
- GBS vaccine eagerly expected

Summary

"Screening" Prevention strategies

- Culture-based GBS prenatal screening
 - To optimize critical factors
 - Improved by selective differential agars
 - False +/False !
- Culture-LAMP combined GBS prenatal screening
 - High sensitivity and negative predictive value
 - 100% specificity and positive predictive value
 - Identification of an 0.8% additional GBS positive specimen
- Rapid intrapartum screening
 - Real time PCR
 - Yes but costs, logistic, ...
 - Need for more clinical and cost effectiveness trial

Meridian 09.10.2012

GUIDELINES

SCREENING

54



Evaluation of *illumigen*® GBS

CHU Liège

Magali Dodémont Gilles Sarlet Julie Descy Cécile Meex Raphaël Boreux & Bacteriology Staff AZ Sint-Lucas, Gent Karlien Vanhouteghem Anne Marie Van den Abeele & Bacteriology Staff

CHR Citadelle Liege Jean Marc Senterre

Meridian for supplying the test kits